1 A step forward, but still inadequate: Australian health professionals' views on the genetics and life

- 2 insurance moratorium
- 3
- 4 Authors:
- 5 # Jane Tiller^{1, 2}, (<u>https://orcid.org/0000-0003-3906-6632</u>)
- 6 Louise Keogh³
- 7 Aideen McInerney-Leo⁴
- 8 Andrea Belcher^{5,6} (<u>https://orcid.org/0000-0002-3331-5637</u>)
- 9 Kristine Barlow-Stewart⁷
- 10 Tiffany Boughtwood^{2,6} (https://orcid.org/0000-0002-9634-3731)
- 11 Penny Gleeson⁸ (https://orcid.org/0000-0003-2798-1649)
- 12 Grace Dowling¹
- 13 Anya E.R. Prince⁹ (https://orcid.org/0000-0002-0086-7881)
- 14 Yvonne Bombard¹⁰
- 15 Yann Joly¹¹
- 16 Martin B Delatycki^{2, 12}
- 17 Ingrid Winship^{13, 14}
- 18 Margaret Otlowski¹⁵ (Orcid.org/0000-0003-4707-4325)
- 19 Paul Lacaze¹ (orchid: 0000-0002-0902-6798)

2021 Affiliations

- ¹ Public Health Genomics, School of Public Health and Preventive Medicine, Monash University,
- 23 Melbourne, Australia
- 24 ² Murdoch Children's Research Institute, Parkville, Australia
- ³ Centre for Health Equity, Melbourne School of Population and Global Health, The University of
- 26 Melbourne, Melbourne, Australia
- 27 ⁴ The University of Queensland Diamantina Institute, University of Queensland, Dermatology
- 28 Research Centre, Brisbane, Australia
- 29 ⁵ Faculty of Medicine, University of Queensland, Brisbane, Australia
- 30 ⁶ Australian Genomics, Melbourne, Australia
- 31 ⁷ Sydney Medical School, University of Sydney, Sydney, Australia
- 32 ⁸ Deakin Law School, Melbourne, Australia
- ⁹ University of Iowa College of Law, Iowa City, United States
- ¹⁰ University of Toronto, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada.
- ¹¹ The Genetic Discrimination Observatory, Department of Human Genetics, McGill University,
- 36 Montreal, Canada
- 37 ¹² Victorian Clinical Genetics Services, Parkville, Australia
- ¹³ Department of Medicine, the University of Melbourne, Melbourne, Australia.
- 39 ¹⁴ Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Australia
- 40 ¹⁵ Faculty of Law and Centre for Law and Genetics, University of Tasmania, Hobart, Australia
- 41
- 42 # corresponding author
- 43 Jane Tiller, LLB, MGenCouns
- 44 Monash University, School of Public Health and Preventive Medicine
- 45 Level 5, 99 Commercial Road, 3004 Melbourne, VIC, Australia
- 46 email: jane.tiller@monash.edu

47 ABSTRACT

48 Background

49 In 2019, the Australian life insurance industry introduced a partial moratorium (ban) limiting the use

- 50 of genetic test results in life insurance underwriting. The moratorium is industry self-regulated and
- applies only to policies below certain financial limits (eg AUD\$500,000 of life cover).
- 52 Methods
- 53 We surveyed Australian health professionals (HPs) who discuss genetic testing with patients, to assess

54 knowledge of the moratorium; reported patient experiences since its commencement; and HP views

- regarding regulation of genetic discrimination (GD) in Australia.
- 56 Results

57 Between April-June 2020, 166 eligible HPs responded to the online survey. Of these, 86% were aware 58 of the moratorium, but <50% had attended related training/information sessions. Only 16% answered 59 all knowledge questions correctly, yet 69% believed they had sufficient knowledge to advise patients. 60 Genetics HPs' awareness and knowledge were better than non-genetics HPs' (p<0.05). There was 61 some reported decrease in patients delaying/declining testing after the moratorium's introduction, 62 however 42% of HPs disagreed that patients were more willing to have testing post-moratorium. 63 Although many (76%) felt the moratorium resolved some GD concerns, most (88%) still have concerns, 64 primarily around self-regulation, financial limits and the moratorium's temporary nature. Almost half 65 (49%) of HPs reported being dissatisfied with the moratorium as a solution to GD. The majority (95%) 66 felt government oversight is required, and 93% felt specific Australian legislation regarding GD is 67 required.

68 Conclusion

69 While the current Australian moratorium is considered a step forward, most HPs believe it falls short
70 of an adequate long-term regulatory solution to GD in life insurance.

71 Key words: genetic discrimination; life insurance; moratorium; ethics; health professional

72 Introduction

Genetic discrimination (GD) is an area of international concern[1-4]. In the context of life insurance, GD can lead to increased premiums or denial of insurance applications. Predictive genetic testing (where an individual has not developed disease but genetic testing can reveal a higher risk of developing disease) can save lives due to preventative interventions or early treatment of disease. In Australia and internationally, research shows that fear of insurance implications deters some at-risk individuals from having clinically-indicated predictive genetic testing or participating in research[5-10].

80

81 In Australia, the issue of GD in health insurance does not arise, because health insurance premiums 82 are community-rated rather than personally risk-rated under the Private Health Insurance Act 2007 83 (Cth). However, life insurance companies can legally ask for and use applicant's genetic test results to 84 make underwriting decisions, under a specific exemption in s46 of the Disability Discrimination Act 85 1992 (Cth) (DDA). Despite consideration of the potential for GD arising from this exemption in 2001-86 03[11], the Australian government continues to allow the life insurance industry to self-regulate their 87 access to and use of applicants' genetic information. The inherently conflicted model of industry self-88 regulation for life insurance raises numerous ethical and societal concerns[12]. These have been 89 reflected in government inquiries into the insurance and financial services industries in recent 90 years[13 14].

91

In 2018, the Australian Parliamentary Joint Committee on Corporations and Financial Services released recommendations arising out of its inquiry into the life insurance industry[14]. These included recommending a ban (moratorium) on life insurers' use of predictive genetic test results for underwriting, as well as recommending government monitoring and introduction of legislation if necessary. The Australian government has not yet responded to these recommendations. However, in 2019, the Financial Services Council (FSC), the peak industry body for Australian life insurers, voluntarily introduced an industry self-regulated moratorium on the use of genetic test results by their
member organisations[15 16]. The FSC moratorium, which applies only to FSC member companies,
restricts insurers' access to and use of genetic test results for applications for life insurance cover for
or below AUD\$500,000 only. Because travel insurance falls within general insurance, as distinct from
life insurance, it is not restricted by the moratorium and genetic test results can legally be used to
discriminate in underwriting, pursuant to s46 of the DDA.

104

105 As a self-regulated industry standard, the FSC moratorium is not legally binding or enforceable; nor is 106 it subject to government regulation or oversight. Legally, the insurance industry's right to use genetic 107 test results in underwriting in accordance with the DDA remains and is not affected by the 108 implementation of the FSC moratorium, which will be reviewed in 2022 and end in 2024, if not 109 renewed. The FSC have a Code of Practice, compliance with which is monitored by an external 110 committee of three persons including a consumer representative, an industry representative and an 111 independent chair[17]. At the time of publication, the FSC moratorium has not been incorporated into 112 the Code of Practice, although we understand that this is FSC's intention in future.

113

114 Health professionals (HPs) are key to ensuring that patients who are considering genetic testing are 115 adequately advised of the potential for life insurance discrimination before testing is undertaken. 116 Further, they often witness the deterrent effects of fears about life insurance implications, or hear 117 firsthand of GD experiences[18]. Australian professional guidelines state that a discussion of insurance 118 implications should be part of each genetic counselling session where relevant[19]. With the progressive mainstreaming of genetic testing in Australia, a greater proportion of clinicians without 119 120 genetics training are discussing genetic testing with patients[20]. A recent systematic review[21] 121 found non-genetics HPs (nurses and physicians) had limited genetics knowledge and were unprepared 122 for integrating genomics into clinical care. However, little is known about non-genetics HPs' 123 knowledge regarding life insurance discrimination, the moratorium, and the implications for patients.

1	2	4

Prior to the introduction of the FSC moratorium, we surveyed genetics professionals in Australia about their patients' experiences regarding life insurance discrimination and their views on regulation of this area [18]. That study demonstrated some deficits both in knowledge regarding use of genetic testing in insurance underwriting, and self-reported confidence in advising patients about insurance implications. It also captured widespread concerns regarding regulation in the area of GD, with the vast majority of HPs reporting a view that current Australian regulations were inadequate to protect patients from GD.

132

133 To our knowledge, there has been no survey of HPs following the introduction of the FSC moratorium. 134 This study forms a key part of the Australian Genetics and Life Insurance Moratorium: Monitoring the 135 Effectiveness and Response (A-GLIMMER) Project - funded by the Australian government[22 23]. The 136 purpose of the Project is to assess the extent to which the FSC moratorium achieves the policy aims 137 identified by the Parliamentary Joint Committee on Corporations and Financial Services. This 138 particular study contributes to that Project by analysing the effectiveness of the FSC moratorium in 139 relation to HPs. The aim of this study is to describe the knowledge, experiences and perspectives of 140 HPs that discuss genetic testing with patients, following the commencement of the FSC moratorium. 141 Where possible, it will also compare those findings with findings from the pre-moratorium research 142 study[18].

143

144 Methods

145 *Population, sampling and recruitment*

The protocol paper for the A-GLIMMER project has been published previously[23]. The population of interest was qualified health professionals working in a health service in Australia, who regularly discuss genetic testing with patients. Eligibility was established through screening questions at the 149 beginning of the questionnaire. A range of targeted recruitment strategies were adopted to capture a

150 broad sample:

- Newsletters emailed directly to members of the Human Genetics Society of Australasia
 (HGSA), Australasian Society of Genetic Counsellors, Royal Australasian College of Physicians,
- and the Australian Genomics Health Alliance
- Social media advertisements (Twitter and Facebook)
- Direct email to colleagues and personal contacts of the authors
- Snowball sampling (requesting HPs and personal contacts forward an email invitation to their
- 157 professional networks)

158 <u>Survey development and data collection</u>

159 We used an online survey conducted using REDCap software[24] (see Supplementary Materials for a 160 copy of the survey). The survey was adapted from our previous survey of HPs administered prior to the commencement of the FSC moratorium[18]. Relevant questions were preserved for comparison, 161 162 and new questions were introduced to determine the impact and effectiveness of the moratorium in 163 relation to HPs' knowledge, experience and views. The adapted survey included sections relating to 164 demographics; awareness, training, and knowledge; patient attitudes, behaviours, and reported experiences; and personal views regarding regulation of GD. Validated scales were unavailable for 165 166 questions specific to the moratorium, however the survey was developed in consultation with a 167 number of clinical and research partners, and was pre-tested with a clinical geneticist, a genetic 168 counsellor and a lay person without health qualifications. Data were mostly collected through closed-169 ended responses using Likert scales and fixed alternative options, with a small number of open-ended 170 questions where free text was allowed. The survey was open for response from April–June 2020,

171

172 <u>Data analysis</u>

Descriptive analysis was conducted for closed-ended questions. Descriptive statistics were reported
for each question included in the results, broken down by total number of HPs, as well as separately

175 by genetics HPs and non-genetics HPs. Six questions evaluated knowledge (true/false/unsure) about 176 aspects of the FSC moratorium and current insurance implications). HPs received a point for every 177 correct answer (range 0–6). A mean knowledge score was calculated for comparison between groups. 178 The percentage of correct answers for each item was also calculated. Knowledge scores were 179 categorised into "good knowledge" (5-6 questions answered correctly), "average knowledge" (3-4 180 correct), and "poor knowledge" (0-2 correct). Z-tests were used to test for significance of differences 181 between groups, with p-values (2-sided) <0.05 considered significant. STATA 14 was used for 182 analysis[25].

183

184 Responses to open-ended questions were reviewed and sorted into common categories, which were 185 reported in detail in the supplementary materials and in summary form with example quotes in the 186 manuscript.

187

188 Results

189 Overall, 166 eligible HPs participated in the online survey. As some HPs discontinued the survey before 190 reaching the end, the number of HPs who answered each individual question varied (range n=144-191 166). To aid readability, the "n" for every reported figure is not given in the text, but is included at 192 each instance in the accompanying figures and tables. Given the diverse recruitment strategies, it is 193 difficult to estimate a total response rate relative to all eligible participants. However, at the time of 194 recruitment, the HGSA distribution list included 484 clinical geneticists (CGs) and genetic counsellors 195 (GCs). Of the 166 HPs who participated, 111 were CGs or GCs, making the response rate for those 196 categories in the profession field an estimated 23%.

197

Table 1 shows the characteristics of the surveyed population. The "Other" category under the profession field is comprised of HPs representing more than 15 different fields, all of whom were eligible for the study as they reported regularly discussing genetic testing with patients. These included surgery, nursing, psychiatry, metabolics, cardiology, pathology, neurology, endocrinology,
 gastroenterology, haematology, immunology, obstetrics, paediatrics, and others (see Supplementary
 Table S1). These HPs are referred to as "non-genetics HPs", as distinguished from "genetics HPs"
 (genetic counsellors, clinical geneticists, and genetics fellows).

205

206 Awareness, knowledge and training (Table 2 and Figure 1)

207 Most HPs (86%) overall, but just over half (53%) of non-genetics HPs were aware of the FSC 208 moratorium. Over half of genetics HPs (55%) reported attending training or information sessions 209 regarding the moratorium and insurance implications of genetic testing training, while few non-210 genetics HPs had done so (7%). There are two well-known fact sheets on the moratorium: the Centre 211 for Genetics Education (CGE) Fact Sheet 20[26], and the FSC insurance and genetics moratorium fact 212 sheet[27]. A majority of HPs (65%) had read at least one of these fact sheets. However, only a third 213 (n=14) of non-genetics HPs had read a fact-sheet, compared to 76% (n=89) of genetics HPs (z=5; 214 p<0.05).

215

216 Many HPs (69%) felt that they had sufficient knowledge about current insurance implications to 217 properly advise clients. On the objective knowledge test, about half (49%) had good knowledge (5-6 218 questions answered correctly) (see Table S2 for question-specific data). More genetics HPs answered 219 questions correctly (mean 4.5/6) than non-genetics HPs (mean 3.1/6) (z=7.3; P<0.05). Of the 50 220 genetics HPs who answered two or more questions incorrectly (average/poor knowledge), about 221 three-quarters (n=38) felt they understood insurance implications for individuals undergoing genetic 222 testing extremely/reasonably well, and almost two-thirds (n=30) felt they had sufficient knowledge to 223 properly advise patients. However, of 25 non-genetics HPs who answered two/more incorrectly, only 224 a quarter felt they understood insurance implications extremely/reasonably well, (n=6) and a fifth 225 (n=5) felt they had sufficient knowledge. These differences between genetics and non-genetics HPs 226 were significant (z=4.3 (understanding) z=3.3 (knowledge), p<0.05).

2	С	7
Z	Z	1

228 Impact on practice and testing (Table 3)

229	HPs were asked in this survey about how often patients either delayed or declined having predictive
230	genetic testing due to life insurance concerns, both before the moratorium was introduced and then
231	after the moratorium was introduced (Fig 2A and 2B). Overall, 63% of HPs said patients delayed testing
232	because of life insurance concerns often/sometimes before the moratorium, and 39% said they
233	delayed often/sometimes after the moratorium was introduced (z=4.15; p<0.05). Similarly, 39% said
234	patients refused testing due to life insurance concerns often/sometimes pre-moratorium, compared
235	with 18% post-moratorium (z=4.18; p<0.05).

236

Although the FSC moratorium does not apply to travel insurance, this can be a source of some confusion for both patients and consumers. GD in travel insurance was raised as an issue by several HPs in free-text responses (see below). When asked about how often patients delay or decline predictive testing due to travel insurance concerns, 11% of HPs said patients delay often/sometimes, and 12% said patients refuse often/sometimes.

- 242

243 <u>Views on the FSC moratorium's effectiveness and regulation (Table 4)</u>

Almost all HPs (93%) agreed/strongly agreed that "consumers are better protected post-moratorium than they were before the moratorium was introduced". Although 76% felt the FSC moratorium resolved some concerns the HPs had about insurance discrimination, 88% still had concerns about insurance discrimination after its introduction.

248

Most HPs agreed/strongly agreed that the FSC moratorium is easy to understand (80%) and easy to explain to patients (76%); however, a number (20% and 24% respectively), disagreed/strongly disagreed, showing a portion of HPs find it difficult to understand and/or explain. HPs were split almost evenly in their views regarding both questions "*patients are less confused than they used to be*

253	about insurance implications of genetic testing" (51% agreed/strongly agreed; 49% disagreed/strongly
254	disagreed) and "patients are more willing to have predictive genetic testing than they were before the
255	moratorium was introduced" (59% agreed/strongly agreed; 41% disagreed/strongly disagreed).
256	
257	The vast majority (95%) of HPs (with no significant difference between genetics and non-genetics HPs
258	(z=0.2; p=0.83)) stated that a formal agreement between government and the life insurance industry
259	(as exists in the UK) is required in Australia (Fig 2C). This question allowed optional free text to allow
260	for HPs to elaborate on their answer (see Table S3 for all free-text responses grouped into categories).
261	Of 149 HPs, 22 elected to elaborate (21 who said yes, 1 who said no). Of those who said yes, one-third
262	expressed concerns with industry self-regulation. For example, Participant 129 (genetic counsellor, 0-
263	5 years' experience) stated, "I think that the industry needs to be held accountable; I don't trust that

264 the self-governing model is enough."

265

Two HPs felt that further regulation may be needed, but the decision should depend on the outcomes of the FSC moratorium, with Participant 127 (genetic pathologist, 15-20 years' experience) stating, *"We need an evidence-based approach. We should wait for results to emerge from the current moratorium."* The HP who said no and chose to elaborate (Participant 109, clinical geneticist, 15-20 years' experience) stated, *"Insurance companies currently load premiums or withhold cover on much less scientific premises than genetic test results. By making these 'special' we do more harm than good by making people afraid of genetic testing and complicating the process".*

273

The vast majority (93%) of HPs also indicated that the Australian government should introduce legislation to regulate the use of genetic test results in life insurance (no significant difference between genetics/non-genetics HPs (z=-0.1; p=0.94)) (Fig 2D). Of 149 HPs, 15 elaborated (13 "yes"; 3 "no") (Table S3). Four HPs expressed mistrust of insurers, with Participant 207 (genetic counsellor, >20 years' experience) stating, "*if it is not in law, why would an insurance company do it?*". Four HPs

commented that legally-enforceable/legislation-based regulation is required to ensure consumer protection; for example, Participant 135 (clinical geneticist, >20 years' experience) noted, "this is the only way to protect people properly and not have the highly undesirable situation where people don't have genetic testing because of insurance concerns and die of preventable disease."

283

284 One HP's reason (Participant 256, Registered Nurse, >20 years' experience) for answering "no" to the 285 government regulating insurer use of genetic information through legislation, appeared to be that 286 insurer use should not be allowed at all, stating, "Sorry, too many instances where insurance 287 companies look to preserving their cash and not interested in helping people with genuine need." 288 Participant 229 (clinical geneticist, 15-20 years' experience) answered no "with the caveat that self-289 regulation is effective and sufficient monitoring is in place" along with 2 others who stated that any 290 regulation should be evidence-based. The other "no" HP (Participant 109, clinical geneticist, 15-20 291 years' experience) explained that, "People accept that information available will be used by insurance 292 companies. They don't generally have a problem with this".

293

When asked about how insurers' compliance with the FSC moratorium on using genetic test results in life insurance should be regulated, 88% of HPs chose "regulation through legally enforceable rules". Thirteen percent (n=20) chose self-regulation by the FSC, though 7 of these also chose "legally enforceable rules" indicating a preference for a blended regulatory approach. Forty-nine percent of HPs felt either very or somewhat dissatisfied with the moratorium as a solution to GD in life insurance. Only 4% felt "very satisfied".

300

301 <u>Benefits and limitations of the moratorium (Table 5)</u>

302 Sixty-two HPs responded to the optional free-text question "In your opinion, what, if any, are/have 303 been the benefits of the moratorium?" Table 5a sets out the categories of benefits that were 304 expressed, with example quotes (see Supplementary Table S4 for full responses). The most common

305 responses were "increased reassurance/patients more willing to have genetic testing" (34%) and 306 "some protection provided" (31%). Sixty-one HPs provided optional feedback to the question, "in your 307 opinion, what, if any, are the limitations of the moratorium?" (Table 5b, Table S4). The most commonly 308 raised limitations were "insurance companies' compliance/ self-regulation" (46%), "financial limits" 309 (44%), and "temporary nature of the moratorium" (31%). Similar issues arose in free-text comments 310 in the final question, "Do you have any final comments?" (Table S5). Of 21 HPs who responded with 311 substantive comments about the FSC moratorium, a third (n=7) raised issues around the need for 312 legislation/enforceability; 2 each expressed concerns with the temporary nature and the unjustness 313 of discrimination based on uncontrollable factors; 1 reiterated the inadequacy of the financial limits; 314 5 reported difficulty with understanding/explaining the moratorium to patients; and 3 expressed 315 concerns with the applicability to travel insurance. No HPs made any positive comments about the 316 moratorium in the final thoughts section.

317

318

319 Discussion

320 In this study, we surveyed Australian health professionals' (HPs) knowledge, experiences, and opinions 321 regarding the current industry self-regulated moratorium on genetic testing and life insurance. We 322 found that most HPs who discuss genetic testing with clients are aware of the FSC moratorium, though 323 knowledge of key aspects of the moratorium could be improved. Both awareness of and knowledge 324 about the moratorium are superior for genetics HPs than non-genetics HPs. Many HPs expressed a 325 view that the moratorium had resolved some of their concerns with GD. However, the majority of HPs 326 still have concerns regarding the potential for GD in life insurance and feel that the moratorium does 327 not adequately address those concerns. Most HPs feel that the moratorium does not represent an 328 adequate long-term regulatory solution for Australia. Specifically, the majority of HPs feel that more 329 stringent consumer protections are required, especially in the form of stronger government regulation 330 or legislation. Key findings of our study are summarized in Figure 3.

331

332 In our previous survey of Australian genetics HPs, conducted before the FSC moratorium was 333 introduced[18], we found that only 9% (n=6/69) of HPs felt regulation at the time was adequate. 334 Now, after the introduction of the FSC moratorium, we still find that >90% believe government 335 regulation and legislation are required. Although the moratorium is seen as a step forward, most 336 Australian HPs remain concerned about the potential for GD, and its impact on patients. We found 337 evidence of recognition from HPs regarding improved consumer protections, compared with the pre-338 moratorium situation, with most HPs agreeing that consumers are better protected now, after the 339 introduction of the FSC moratorium. When asked about benefits of the moratorium, some HPs cited 340 increased willingness of patients to have genetic testing. However, despite some reported reduction 341 in patients delaying or refusing testing for insurance reasons, more than 40% of HPs still disagreed 342 that patients are more willing to have testing following the introduction of the FSC moratorium, 343 suggesting the desired impact of the moratorium has not been fully achieved.

344

345 Although about half of HPs surveyed expressed some satisfaction with the FSC moratorium as a 346 solution to GD in life insurance, about half were either somewhat or very dissatisfied with it, and a 347 vast majority still had concerns about insurance discrimination post-moratorium. Primary concerns, 348 expressed in free-text comments, centred around the nature of industry self-regulation, lack of 349 government oversight, the financial limits on the moratorium and its temporary nature. Comments 350 provided by HPs showed negative opinions - including distrust of insurers, the conflicted nature of 351 industry self-regulation, the need for more stringent government regulation, the inadequacy of the 352 current financial limits, and the temporary nature of the FSC moratorium (and the uncertainty this 353 creates for patients in the future). A small minority of HPs felt that government regulation was not 354 required, as either the moratorium was adequate or the government should wait and see whether it 355 is effective before introducing further regulation.

356

357 Many countries have banned or restricted life insurers' access to genetic test results for underwriting 358 purposes[28-30]. For example, Canada has implemented the *Genetic Nondiscrimination Act* (2017) 359 (GNDA), which prevents insurers from using genetic test results, and the US' Genetic Information 360 Nondiscrimination Act (2008) (GINA) bans the use of genetic test results in health insurance and 361 employment contexts. The UK's moratorium (known since 2018 as the Code on Genetic Testing and 362 Insurance[31]) was established in 2001 as an agreement between the insurance industry and the UK 363 Government, to protect consumers in relation to the use of predictive genetic test results. A single 364 exception applies to predictive genetic tests for Huntington's disease where the life insurance policy 365 coverage is above £500,000 (~AUD\$910,000).

366

Almost all HPs surveyed believe that a formal agreement between government and industry is required for Australia. Further, most HPs felt that any moratorium should be regulated through legally enforceable rules from the Australian government, including specific legislation to regulate life insurers' use of genetic test results. Our findings demonstrate that HPs who offer genetic testing to patients believe that the current policy situation is still inadequate and lacks sufficient consumer
protections. Given that in our previous study 62% of HPs considered Australia should introduce such
legislation, and 93% of current HPs considered that legislation was needed, it appears that the current
FSC moratorium has not altered that perception for the majority of HPs.

375

Although the FSC moratorium may soon be included in the FSC Code of Practice[17], compliance with this Code is monitored by a committee of three individuals and is not subject to any legal or regulatory oversight from government. There are no pathways for enforcement by consumers (other than complaints to the Financial Ombudsman Service), and the sanctions which can be imposed lack any legal weight or punitive power. Thus, inclusion of the moratorium in the Code in future may not alleviate HPs concerns regarding lack of government oversight of this issue.

382

The demographics of HPs in this study are similar to those of our previous study[18]. However, the current cohort is larger (n=166, compared with n=87 previously) and more diverse due to the expanded recruitment strategy. This survey has highlighted the diversity of health professionals who are discussing genetic testing with patients, in line with the mainstreaming of genetic testing noted earlier. This has also captured, for the first time in Australia, the perceptions of these HPs on this issue.

388

389 Although there was consensus among most HPs from genetics and non-genetics backgrounds on key 390 issues, including regulation, there was also divergence between genetics and non-genetic HPs in some 391 areas. Areas of divergence include awareness of the FSC moratorium, with only about half of non-392 genetics HPs who discuss genetic testing with patients being aware of the moratorium. Our results in 393 this regard are consistent with other studies that report poor awareness or understanding of local 394 non-discrimination laws/policies by HPs [32-34]. However, given the importance of considering 395 insurance issues where relevant before deciding whether to have a genetic test, this lack of awareness 396 is somewhat concerning, and raises questions about dissemination and how to more effectively raise

awareness, particularly among non-genetics HPs. The numbers of genetics and genetics HPs who had
read either the CGE or FSC fact sheets indicate that these are a reasonable method of disseminating
information to genetics HPs but not so effective for non-genetics HPs.

400

401 Another area of distinction between genetics and non-genetics HPs was in objective knowledge. When 402 only considering genetic HPs, 81% felt they had sufficient knowledge of insurance implications to 403 properly advise patients, which has increased from our previous research (61%; n=53/87)[18]. 404 However, only a small fraction of both genetics and non-genetics HPs answered all 6 questions about 405 key aspects of the FSC moratorium correctly, and about half had average or poor knowledge. For non-406 genetics HPs, there was a reasonable match between subjective and objective lack of knowledge. This 407 is consistent with international studies of non-genetics HPs, which found a correlation between HPs' 408 subjective and objective knowledge levels regarding genetic non-discrimination regulations[35] and 409 genetics generally [36]. However, although genetics HPs were more knowledgeable than non-genetics 410 HPs, they appeared to overestimate their knowledge more than non-genetics HPs, indicating some 411 mismatch between subjective and objective knowledge.

412

413 An area of historical misinformation is that of the impact of GD on health insurance. In our previous 414 survey[18], 15% of HPs incorrectly stated that genetic information could be used for health insurance 415 policies in Australia. In the current survey, a similar number (17%) of genetics HPs still answered this 416 question incorrectly, as well as 50% of non-genetics HPs. The knowledge gap between genetic and 417 non-genetic HPs overall was sizable, highlighting the need to train a wider range of HPs with the 418 mainstreaming of genetic testing. Surprisingly, given the recent policy changes and need for 419 dissemination and education around these changes, similar numbers of genetics HPs reported 420 attending training in our previous survey (51%) as this survey (55%). Further, a smaller percentage of 421 genetics HPs reported having read the CGE fact sheet (68%) than previously reported (85%)[18]. This

422 may explain the knowledge gaps despite clinician confidence (HPs who feel they have sufficient423 knowledge may be less likely to seek out additional resources).

424

A significant finding of the study is that many HPs (50%) believe the FSC moratorium applies to travel insurance, or are unsure of its application. As discussed, travel insurers are not restricted by the moratorium. Several HPs raised concerns about insurance implications for travel insurance in free-text comments regarding limitations of the moratorium and in the "final thoughts" section. This provides further support for the contention that broader government regulation and oversight of the use of genetic test results in insurance underwriting is required to adequately protect consumers.

431

Strengths of the current study include being the first of its kind to report HP views and experiences since the introduction of the FSC moratorium. Also, to our knowledge, our study provides the first example of a survey of HPs conducted both before and after the introduction of a major policy change regarding GD and life insurance. By asking similar questions as our previous (pre-moratorium) survey, we were able to undertake comparative analysis pre- and post-moratorium. Our survey reached a wide range of HPs, covering traditional genetics HPs as well as other clinicians who discuss genetic testing with patients.

439

440 Limitations of our study include the relatively small number of non-genetics HPs surveyed, which may 441 limit the generalisability to this group. HPs were asked some questions about patient experiences, 442 which is arguably second-hand information. Other studies, which will seek firsthand experiences/perceptions of patients and consumers, are being developed as part of the A-GLIMMER 443 444 Project[37] to address this limitation. Given the rising prominence of the issue of life insurance 445 discrimination in Australia, response bias is a potential limitation. We attempted to address this by 446 making it an option for HPs to remain anonymous if they preferred. Further, views expressed by HPs 447 who were happy to be contacted (~20% of HPs) will be explored further through qualitative interviews,

in a subsequent study. Our survey was conducted less than a year after the introduction of the FSC
moratorium (9 months). Although this was intentional to ensure data collection and analysis could
take place to inform the review of the moratorium, waiting longer could have resulted in different
responses and experiences from HPs. As the survey was conducted online and in early 2020, it is not
expected that COVID restrictions significantly affected participation.

453

454 Conclusion

455 Many Australian genetic HPs know about the FSC moratorium and have knowledge of its specifics; 456 however, some genetic HPs and many non-genetics HPs do not. Australian HPs report some 457 improvement for consumers as a result of the moratorium's introduction, but concerns about GD in 458 life insurance remain. HPs describe strong views about perceived limitations of the moratorium, 459 including industry self-regulation and lack of government oversight, as well as the inadequacy of the 460 current financial limits and the uncertainty around the moratorium's temporary nature. A majority of 461 Australian HPs believe government oversight of the FSC moratorium is required, and that legislation 462 regarding genetic testing and life insurance should also be considered in Australia. Our findings will 463 assist with developing recommendations for the Australian government to consider future policy and 464 regulatory changes in this area, and will be of interest to other jurisdictions internationally who are 465 grappling with similar issues around the regulation of GD in life insurance.

466

467

468

469

470 Figure legends

471 Figure 1: Awareness, knowledge, training

472 Figure 2: Patient impact and views on regulation

473 Figure 3: Summary of findings

474 **Declarations**

475

476 Funding (information that explains whether and by whom the research was supported)

The project is supported by a grant from the Australian Government's Medical Research Future Fund
(MRFF), ref 76721. AML is funded by a National Health and Medical Research Council (NHMRC) Early
Career Fellowship (ID 1158111). PL is supported by a National Heart Foundation Future Leader
Fellowship (ID 102604).

481

482 Conflicts of interest/Competing interests (include appropriate disclosures)

483 The authors declare no conflicts of interest or competing interests

484

488

485 Availability of data and material (data transparency)

486 Numerous data are made available via supplementary materials. Additional data can be made487 available on reasonable request.

- 489 **Code** availability (software application or custom code)
- 490 N/A

491 492 Authors' contributions (optional: please review the submission guidelines from the journal

- 493 whether statements are mandatory)
- 494 495

496 *Ethics approval (include appropriate approvals or waivers)*

- This project was granted approval by the Monash University Human Research Ethics Committee on 11
 March 2020, ID number 22576, and was performed in accordance with the ethical standards as laid
 down in the 1964 Declaration of Helsinki.
- 500

501 **Consent to participate (include appropriate statements)**

- 502 The Explanatory Statement provided to participants includes the following statement: "Participation 503 is completely voluntary and you are able to withdraw at any time. However, if you chose to remain 504 anonymous in completing the survey, we will not be able to identify your data in order to exclude it 505 from analysis."
- 506

507 The first question of the online survey completed by participants (following the reading of the 508 Explanatory Statement) was as follows:

- 509 "By continuing with this survey, you give your consent to being a participant in this research project
 - Continue with survey
- 510 511

I do not want to continue with this survey" (survey ended if this response was selected)

512

513 **Consent for publication (include appropriate statements)**

514 The Explanatory Statement provided to participants includes the following statement: "The data 515 collected will be de-identified so that the source of each response is not known, and the de-identified 516 data will be analysed and submitted for publication in a peer-reviewed journal."

517

518

519 References

- 520 1. Joly Y, Dalpé G, Dupras C, et al. Establishing the International Genetic Discrimination Observatory.
 521 Nature Genetics 2020;52(5):466-68 doi: 10.1038/s41588-020-0606-5[published Online First:
 522 Epub Date]|.
- 523 2. Joly Y, Dupras C, Pinkesz M, et al. Looking Beyond GINA: Policy Approaches to Address Genetic
 524 Discrimination. Annual Review of Genomics and Human Genetics 2020;**21**(1):491-507 doi:
 525 10.1146/annurev-genom-11119-011436[published Online First: Epub Date]].
- 3. Joly Y, Feze IN, Song L, et al. Comparative Approaches to Genetic Discrimination: Chasing
 Shadows? Trends in Genetics 2017
- 4. Tiller J, Otlowski M, Lacaze P. Should Australia Ban the Use of Genetic Test Results in Life
 Insurance? Frontiers in Public Health 2017;5(330) doi: 10.3389/fpubh.2017.00330[published
 Online First: Epub Date]].
- 5. Keogh LA, Niven H, Rutstein A, et al. Choosing not to undergo predictive genetic testing for
 hereditary colorectal cancer syndromes: expanding our understanding of decliners and
 declining. Journal of Behavioral Medicine 2017:1-12
- 6. Keogh LA, Otlowski M. Life insurance and genetic test results: a mutation carrier's fight to achieve
 full cover. Med J Aust 2013;199(5):363-66
- 536 7. Keogh LA, van Vliet CM, Studdert DM, et al. Is uptake of genetic testing for colorectal cancer
 537 influenced by knowledge of insurance implications? Medical Journal of Australia
 538 2009;191(5):255
- 8. Smit AK, Keogh LA, Newson AJ, et al. Exploring the Potential Emotional and Behavioural Impact of
 Providing Personalised Genomic Risk Information to the Public: A Focus Group Study. Public
 Health Genomics 2015;**18**(5):309-17 doi: 10.1159/000439246[published Online First: Epub
 Date]].
- 543 9. Green RC, Lautenbach D, McGuire AL. GINA, Genetic Discrimination, and Genomic Medicine. New
 544 England Journal of Medicine 2015;**372**(5):397-99 doi: 10.1056/NEJMp1404776[published
 545 Online First: Epub Date]|.
- 546 10. Wauters A, Van Hoyweghen I. Global trends on fears and concerns of genetic discrimination: a
 547 systematic literature review. J Hum Genet 2016;61(4):275-82 doi:
 548 10.1038/jhg.2015.151[published Online First: Epub Date]].
- 549 11. Australian Law Reform Commission. Essentially Yours: The Protection of Human Genetic
 550 Information in Australia. Secondary Essentially Yours: The Protection of Human Genetic
 551 Information in Australia 2003. http://www.alrc.gov.au/publications/report-96.
- 12. Newson AJ, Tiller J, Keogh LA, et al. Genetics and Insurance in Australia: Concerns around a Self Regulated Industry. Public Health Genomics 2017;**20**(4):247-56
- 13. Hayne K. Final Report Royal Commission into Misconduct in the Banking, Superannuation and
 Financial Services Industry. Canberra, 2019.
- 14. Commonwealth of Australia. Parliamentary Joint Committee on Corporations and Financial
 services life insurance industry. Secondary Parliamentary Joint Committee on Corporations
 and Financial services life insurance industry 2018.
 https://www.aph.gov.au/Parliamentary Business/Committees/Joint/Corporations and Financial
- 559https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Corporations_and_Fin560ncial_Services/LifeInsurance/Report.
- 561 15. Financial Services Council. FSC ANNOUNCES MORATORIUM ON GENETIC TESTS FOR LIFE
 562 INSURANCE TO START IN JULY 2019, 2018.
- 563 16. Financial Services Council. FSC Standard No. 11: Moratorium on Genetic Tests in Life Insurance,
 2019.
- 565 17. Financial Services Council. Life Insurance Code of Practice, 2019.
- 18. Tiller J, Keogh L, Wake S, et al. Genetics, insurance and professional practice: Survey of the
 Australasian clinical genetics workforce. Frontiers in Public Health 2018;6:333
- 568 19. Human Genetics Society of Australasia. Process of Genetic Counselling. Sydney, 2008.

- 20. Otlowski M, Tiller J, Barlow-Stewart K, et al. Genetic testing and insurance in Australia. Australian
 Journal for General Practitioners 2019;48:96-99
- 21. White S, Jacobs C, Phillips J. Mainstreaming genetics and genomics: a systematic review of the
 barriers and facilitators for nurses and physicians in secondary and tertiary care. Genetics in
 Medicine 2020;22(7):1149-55 doi: 10.1038/s41436-020-0785-6[published Online First: Epub
 Date]].
- 575 22. Tiller J, Winship I, Otlowski MF, et al. Monitoring the genetic testing and life insurance
 576 moratorium in Australia: a national research project. Medical Journal of Australia 2021 doi:
 577 https://doi.org/10.5694/mja2.50922[published Online First: Epub Date]|.
- 578 23. Tiller J, McInerney-Leo A, Belcher A, et al. Study protocol: the Australian genetics and life
 579 insurance moratorium-monitoring the effectiveness and response (A-GLIMMER) project.
 580 BMC Med Ethics 2021;22(1):63 doi: 10.1186/s12910-021-00634-2[published Online First:
 581 Epub Date]|.
- 582 24. Harris PA, Taylor R, Thielke R, et al. A metadata-driven methodology and workflow process for
 583 providing translational research informatics support. J Biomed Inform 2009;42(2):377-81
- 584 25. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015.
- 26. Centre for Genetics Education. Fact Sheet 20 Life insurance products and genetic testing in
 Australia Sydney, 2019.
- 587 27. Financial Services Council. Genetic tests and applying for life insurance Key Facts, 2019.
- 28. Prince AER. Comparative perspectives: regulating insurer use of genetic information. European
 Journal of Human Genetics 2019;27(3):340-48 doi: 10.1038/s41431-018-0293-1[published
 Online First: Epub Date]|.
- 29. Otlowski M, Taylor S, Bombard Y. Genetic discrimination: international perspectives. Annual
 review of genomics and human genetics 2012;13:433-54
- 30. Rothstein MA, Brothers KB. Banning Genetic Discrimination in Life Insurance Time to Follow
 Florida's Lead. New England Journal of Medicine 2020;**383**(22):2099-101 doi:
 10.1056/NEJMp2024123[published Online First: Epub Date]|.
- 596 31. HM Government and Association of British Insurers. Code on Genetic Testing and Insurance.
 597 Secondary Code on Genetic Testing and Insurance 2018.
 598 https://www.abi.org.uk/globalassets/files/publications/public/genetics/code-on-genetic-
- 599 testing-and-insurance-final.pdf.
- Shields AE, Burke W, Levy DE. Differential use of available genetic tests among primary care
 physicians in the United States: results of a national survey. Genetics in medicine
 2008;10(6):404-14
- 33. Lowstuter KJ, Sand S, Blazer KR, et al. Influence of genetic discrimination perceptions and
 knowledge on cancer genetics referral practice among clinicians. Genetics in Medicine
 2008;10(9):691-98
- 34. Petit C, Croisetière A, Chen F, et al. Are pharmacists from the province of Quebec ready to
 integrate pharmacogenetics into their practice. Pharmacogenomics 2020;**21**(4):247-56 doi:
 10.2217/pgs-2019-0144[published Online First: Epub Date]|.
- 35. Laedtke AL, O'Neill SM, Rubinstein WS, et al. Family Physicians' Awareness and Knowledge of the
 Genetic Information Non-Discrimination Act (GINA). Journal of Genetic Counseling
- 611 2012;21(2):345-52 doi: 10.1007/s10897-011-9405-6[published Online First: Epub Date]|.
 612 36. Douma KF, Smets EM, Allain DC. Non-genetic health professionals' attitude towards, knowledge
 613 of and skills in discussing and ordering genetic testing for hereditary cancer. Familial cancer
 614 2016;15(2):341-50
- 37. Tiller J, McInerney-Leo A, Belcher A, et al. Study protocol: the Australian genetics and life
 insurance moratorium monitoring the effectiveness and response (A-GLIMMER) project.
 BMC Medical Ethics 2021;(in press) doi: <u>https://doi.org/10.1186/s12910-021-00634-</u>
 2[published Online First: Epub Date]].
- 619

Demographic	Category	Number (%)
	Female	124 (75%)
Sex	Male	40 (24%)
	Other	2 (1%)
	ACT	4 (2%)
	NSW	41 (25%)
	NT	1 (1%)
Location	QLD	17 (10%)
Location	SA	6 (4%)
	TAS	4 (2%)
	VIC	65 (40%)
	WA	28 (17%)
	Associate genetic counsellor	59 (36%)
	Certified genetic counsellor	38 (23%)
Profession	Clinical Geneticist	14 (8%)
	Genetics Fellow	10 (6%)
	Other	45 (27%)
	0-5 years	60 (36%)
	6-10 years	33 (20%)
Years of Experience	11-15 years	21 (13%)
	15-20 years	21 (13%)
	> 20 years	31 (18%)
Average number of	0-5	68 (40%)
appointments with	6-10	70 (41%)
patients considering	11-20	24 (14%)
resting (bei iortingut)	>20	8 (5%)

Table 1: Characteristics of the surveyed population (n=166)

Table 2: Awareness, knowledge, training

Question			Responses	Genetics HPs (%)	Non-genetics HPs (%)	TOTAL (%)
Are you aware that there was a change in policy on 1 July 2019 and a moratorium was)	3/121 (2)	21/45 (47)	24/166 (14)
introduced on the use of genetic testing in life insurance underwriting? (n=166)			s	118/121 (98)	24/45 (53)	142/166 (86)
		My	y health service	64/118 (54)	7/24 (29)	71/142 (50)
[if yes] How d	id you become aware? (n=142)	A r	news source	12/118 (10)	10/24 (42)	22/142 (15)
* more than	one option could be selected	HG	SA	96/118 (81)	4/24 (17)	100/142 (70)
		Insurance industry		4/118 (3)	0/24 (0)	4/142 (3)
Has your he	alth service provided, or have	Ye	s, formal training	7/121 (6)	0/45 (0)	7/166 (4)
you attende sessions re	d, any training or information garding the moratorium and ce implications of genetic	Ye ses	s, information ssions	60/121 (49)	3/45 (7)	63/166 (38)
IIISUI dil	testing? (n=166)	No)	54/121 (45)	42/45 (93)	96/166 (58)
	-	Ext	tremely well	12/121 (10)	0/45 (0)	12/166 (7)
How well do	you feel you now understand	Re	asonably well	89/121 (74)	17/45 (38)	106/166 (64)
undergoi	ng genetic testing? (n=166)	No	ot particularly well	17/121 (14)	17/45 (38)	34/166 (20)
	001 111 01 (11)	No	ot well at all	3/121 (2)	11/45 (24)	14/166 (8)
Do you feel y about the cu	you have sufficient knowledge rrent insurance implications of	Ye	S	98/121 (81)	16/45 (36)	114/166 (69)
genetic	testing to properly advise patients? (n=166)	No)	23/121 (19)	29/45 (64)	52/166 (31)
	The updated HGSA position statement on Genetic		im aware of it and I ve read it	49/117 (42)	9/42 (21)	58/158 (37)
	Testing and Life Insurance (updated after announcement of moratorium) Fact Sheet 20 published by the Centre for Genetics Education (updated mid- 2019)	I am aware of it, but have not yet read it		42/117 (36)	13/42 (31)	55/158 (35)
		l a	im not aware of it	26/117 (22)	20/42 (48)	46/158 (29)
		I am aware of it and I have read it		79/117 (68)	7/42 (17)	86/158 (54)
Are you aware of,		l a ha	m aware of it, but ve not yet read it	17/117 (15)	6/42 (14)	23/158 (15)
and have		١a	im not aware of it	21/117 (18)	28/42 (67)	49/158 (31)
these fact sheets?	The Financial Services Council (FSC) Standard No 11 on Genetic testing (updated to include the moratorium in		im aware of it and I ve read it	29/117 (25)	6/42 (14)	35/158 (22)
(n=158)			m aware of it, but ve not yet read it	42/117 (36)	7/42 (17)	49/158 (31)
	mid-2019)	l a	im not aware of it	46/117 (39)	28/42 (67)	74/158 (47)
		I am aware of it and I have read it		51/117 (44)	11/42 (26)	62/158 (39)
	The FSC fact sheet on the life insurance moratorium	I am aware of it, but have not yet read it		18/117 (15)	2/42 (5)	20/158 (13)
			im not aware of it	48/117 (41)	28/42 (67)	76/158 (48)
Number of knowledge questions answered correctly (n=146) (for question-specific data see		0 1 "Poor knowledge"		1/110 (1)	4/36 (11)	5/146 (3)
				0/110 (0)	5/36 (14)	5/146 (3)
		2		1/110 (1)	4/36 (11)	5/146 (3)
Sup	plementary Table S2)	3"Average4knowledge"	14/110 (13)	7/36 (19)	21/146 (14)	
Mean	score (Genetics HPs)· 1 5		knowledge"	34/110 (31)	5/36 (14)	39/146 (27)
Mean sco	pre (Non-genetics HPs): 3.1	5 "Good	41/110 (37)	7/36 (19)	48/146 (33)	
		6	6 knowledge"	19/110 (17)	4/36 (11)	23/146 (16)

Table 3: Impact on practice and clients

Question		Responses	Genetics HPs (%)	Non-genetics HPs (%)	TOTAL (%)
Is there a	On your consent form, where you have a specific form for	Yes	34/38 (89)	9/13 (69)	43/51 (84)
about	predictive genetic testing in adults (n=51)	No	4/38 (11)	4/13 (31)	8/51 (16)
implications	On your consent form, where	Yes	60/75 (80)	6/24 (25)	66/99 (67)
(n=150)	all genetic testing (n=99)	No	15/75 (20)	18/24 (75)	33/99 (33)
Has your conse	nt form been updated following	Yes	24/113 (21)	4/38 (11)	28/151 (18)
the introduction	on of the moratorium on 1 July	No	67/113 (59)	8/38 (21)	75/154 (50)
	2019? (n=151)	I don't know	22/113 (19)	26/38 (68)	48/154 (32)
	Due to life, income or	Never	1/121 (1)	5/45 (11)	6/154 (4)
	trauma/critical illness	Rarely	41/121 (34)	11/45 (24)	52/154 (34)
	insurance concerns, before	Sometimes	68/121 (56)	19/45 (42)	87/154 (56)
How often do	introduced?	Often	5/121 (4)	5/45 (11)	10/154 (6)
you estimate	Due to life income or	Never	12/121 (10)	5/45 (11)	17/154 (11)
patients	trauma/critical illness	Rarely	62/121 (51)	15/45 (33)	77/154 (50)
delayed	insurance concerns, after the	Sometimes	40/121 (33)	18/45 (40)	58/154 (38)
testing	moratorium was introduced?	Often	0/121 (0)	2/45 (4)	2/154 (1)
(n=154)	Due to travel insurance concerns?	Never	47 /121 (39)	14/45 (31)	61/154 (40)
		Rarely	60/121 (49)	16/45 (36)	76/154 (49)
		Sometimes	7/121 (6)	5/45 (11)	12/154 (8)
		Often	0/121 (0)	5/45 (11)	5/154 (3)
	Due to life, income or	Never	11/121 (9)	7(16)	17/154 (11)
	trauma/critical illness insurance concerns, before the moratorium was	Rarely	76/121 (63)	12/45 (27)	77/154 (50)
		Sometimes	26/121 (21)	19/45 (42)	58/154 (38)
How often do	introduced?	Often	2 /121 (2)	2/45 (4)	2/154 (1)
you estimate	Due to life income or	Never	28/121 (23)	6/45 (13)	34/154 (22)
patients	trauma/critical illness	Rarely	75/121 (62)	18/45 (40)	93/154 (60)
predictive	insurance concerns, after the	Sometimes	11/121 (9)	15/45 (33)	26/154 (17)
testing	moratorium was introduced?	Often	0/121 (0)	1/45 (2)	1/154 (1)
(n=154)		Never	56/121 (46)	16/45 (36)	72/154 (47)
	Due to travel insurance	Rarely	50/121 (41)	14/45 (31)	64/154 (42)
	concerns?	Sometimes	8/121 (7)	8/45 (18)	16/154 (10)
		Often	0/121 (0)	2/45 (4)	2/154 (1)
Since the introduction of the moratorium, have patient/s told you about having had an adverse		Yes	3/114 (3)	2/39 (5)	5/153 (3)
insurance outcome on the basis of genetic test results? (for example, having difficulty obtaining a policy, having an increased premium, or having a policy application denied)? (n=153)		No	111/114 (97)	37/39 (95)	148/153 (97)

Table 4: Views on FSC moratorium and regulation

Question		Responses	Genetics HPs (%)	Non-genetics HPs (%)	TOTAL (%)
		Strongly agree	0/113 (0)	0/35 (0)	0/145 (0)
	The moratorium is easy to	Agree	89/110 (81)	27/35 (77)	116/145 (80)
	understand (n=145)	Disagree	18/110 (16)	6/35 (17)	24/145 (17)
		Strongly disagree	3/110 (3)	2/35 (6)	5/145 (3)
		Strongly agree	1/110 (1)	0/35 (0)	1/144 (1)
	The moratorium is easy to explain to	Agree	80/109 (73)	28/35 (80)	108/144 (75)
	patients (n=144)	Disagree	25/109 (23)	5/35 (14)	30/144 (21)
		Strongly disagree	3/109 (3)	2/35 (6)	5/144 (3)
	Dationts are loss confused than they	Strongly agree	5/109 (5)	0/35 (0)	5/144 (3)
	used to be about insurance	Agree	51/109 (47)	17/35 (49)	68/144 (47)
	implications of genetic testing	Disagree	49/109 (45)	17/35 (49)	66/144 (46)
Please	(n=144)	Strongly disagree	4/109 (4)	1/35 (3)	5/144 (3)
indicate the		Strongly agree	6/109 (5)	0/35 (0)	6/144 (4)
which you	predictive genetic testing than they	Agree	60/109 (55)	19/35 (54)	79/144 (55)
agree with	were before the moratorium was	Disagree	39/109 (36)	15/35 (43)	54/144 (38)
the following	introduced (n=144)	Strongly disagree	4/109 (4)	1/35 (3)	5/144 (3)
statements		Strongly agree	5/109 (5)	2/35 (6)	7/144 (5)
	The moratorium has resolved some	Agree	82/109 (75)	21/35 (60)	103/144 (72)
	concerns I had about insurance discrimination (n=144)	Disagree	21/109 (19)	10/35 (29)	31/144 (22)
		Strongly disagree	1/109 (1)	2/35 (6)	3/144 (2)
		Strongly agree	22/109 (20)	4/35 (11)	26/144 (18)
	moratorium, I still have concerns	Agree	76/109 (70)	25/35 (71)	101/144 (70)
	about insurance discrimination	Disagree	9/109 (8)	4/35 (11)	13/144 (9)
	(n=144)	Strongly disagree	2/109 (2)	2/35 (6)	4/144 (3)
	Concumers are better protected	Strongly agree	18/109 (16)	2/35 (6)	20/144 (14)
	post-moratorium than they were	Agree	84/109 (77)	30/35 (86)	114/144 (79)
	before the moratorium was	Disagree	7/109 (6)	3/35 (9)	10/144 (7)
	introduced (n=144)	Strongly disagree	0/109 (0)	0/35 (0)	0/144 (0)
		Very satisfied	6/113 (5)	0/36 (0)	6 /149 (4)
Based on you	r professional experience, how do you	Somewhat satisfied	52/113 (46)	18/36 (13)	70/149 (47)
discrim	ination in life insurance? (n=149)	Somewhat dissatisfied	49/113 (46)	12/36 (9)	61/149 (41)
		Very dissatisfied	6 /113 (5)	6/36 (4)	12/149 (8)
In your opin	ion, how should insurers' compliance	Self-regulation by the life insurance industry (FSC)	16/113 (14)	4/36 (11)	20/149 (13)
with the moratorium on using genetic test results in life insurance be regulated? (n=149) * more than one option could be selected		Regulation through legally enforceable rules	102/113 (90)	29/36 (81)	131/149 (88)
		Other	2/113 (2)	3/36 (8)	5/149 (3)
In the UK, there is a moratorium that involves a formal agreement between the UK government and the Life Insurance Industry. Do you think a formal agreement between the Australian government and industry (Financial Services Council) is required on this issue in Australia? (n=149)		Yes	108/113 (96)	33/36 (92)	141/149 (95)
		No	5/113 (4)	3/36 (8)	8/149 (5)
Do you think the Australian government should		Yes	105/113 (93)	34/36 (94)	139/149 (93)
test results in life insurance? (n=149)		No	8/113 (7)	2/36 (6)	10/149 (7)

Benefit (n=62)	n (%)*	Example quote(s)	Participant # (qualification, yrs' experience)
Increased reassurance/ patients more	21 (34%)	Easing concerns for patients who may now have some level of cover if at high genetic risk. By doing this it lessens the potential negative implications of predictive testing and therefore decision making can be focused more on the health implications.	P21 (GC, 10-15 y)
genetic testing		It's a step in the right direction and patients with minor concerns/reluctance feel reassured	P108 (GC, 0-5 y)
Some	19	Provides at least some level of insurance that may not have been available at all previously	P42 (GC, 10-15 y)
provided	(31%)	People can access some level of insurance without the threat of discrimination based on their genetic test result	P199 (GC, 0-5 y)
Increased clarity	9 (15%)	From my practice point of view, having some clear guidelines to present to clients/patients, rather than it all being very dependent on the individual insurer.	P129 (GC, 0-5 y)
Family implications	Family implicationsMost people are concerned about what the insurance implications a children. It is helpful to be able to let them know that their children of to disclose their parent's health conditions not their genetic test results		Р136 (GC, 0-5 у)
Heightened awareness/ recognition of issue	5 (8%)	More awareness of the issue, hopefully future stronger protections for patients depending on how effective the moratorium can be shown to be currently.	P130 (GC, 6-10 y)
"Step in the right direction"	3 (5%)	It is a step in the right direction but insurance concerns are still present for many patients and providers	Р108 (GC, 0-5 у)
Provides time	2 (3%)	Gives time to find better solution	P98 (GC, 15-20 y)
	* partio GC=Ge		

Table 5a: Perceived benefits of the current genetics and life insurance moratorium in Australia

Limitation (n=64)	n (%)*	Example quote(s)	Participant # (qualification, yrs' experience)
Insurance companies'	29	It would be better if there was NO discrimination at all, that was made law and insurance companies held accountable (not self-regulated).	P129 (GC, 0-5 y)
compliance/ self-regulation	(45%)	It is self-regulated and not legally enforceable, so only as good as the trust in the industry generally	P89 (GC <i>,</i> 0-5 y)
Financial limits	28 (44%)	The limit on cover is relatively low. Despite industry assurance that most policies fall below this threshold a significant number of patients see this as limiting	P229 (CG 15-20 y)
		The amounts are too low and won't give enough reassurance to some.	P135 (CG >20 y)
Temporary nature of moratorium	17 (27%)	The uncertainty about how long it will be in place - we need this to be PERMANENT to enable patients not to fear having genetic testing because of insurance concerns as genetic testing can really influence their physical AND psychological health	P149 (GC 15-20 y)
		The uncertainty of how this will apply in the future if someone wants to take out a policy in a few years and the moratorium no longer applies.	P173 (GC, 0-5 y)
Restricted application	8 (13%) Not all insurers are FSC Members. It doesn't apply to all life insurance policies, only those under certain amounts. Only applies to policies from 1 July 2019, ie not pre-existing too.		Р42 (GC, 11-15 у)
Travel insurance not covered	3 (5%)	3 (5%) Travel insurance is a major exclusion. Many patients are concerned about implications for travel insurance especially when their work or family takes them to high cost medical care in countries such as USA.	
Lack of dissemination	2 (3%)	Many financial advisors and workers in the industry seem unaware of the moratorium.	P207 (CG, >20 y)
	* partio GC=Ge		

Table 5b: Perceived limitations of the current genetics and life insurance moratorium in Australia



Figure 1: Awareness, knowledge, training



Figure 2: Patient impact and views on regulation

Most HPs who discuss genetic testing with patients are aware of the FSC moratorium

BUT

AND

Knowledge of key terms could be improved HPs perceive some improvement for consumers

BUT

Australia should introduce specific legislation to regulate the use of genetic information

HPs believe the government should be involved in any moratorium agreement

KEY FINDINGS

HP concerns about genetic discrimination in life insurance remain

Figure 3: Key findings